Advances in prostate specific antigen biosensors-impact of nanotechnology

Negahdary, Masoud; Sattarahmady, N.; Heli, H.

doi:10.1016/j.cca.2020.01.028

Cited by 42 publications

(22 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthily, Ab 1 and Ab 2 were different antibodies. Ab 1 was a capture antibody that captured the test antigen, while Ab 2 was a detection antibody that could bind to the captured antigen . Both Ab 1 and Ab 2 had high specificity for antigens, and there was no competitive binding between them and antigens because they bind antigens at different sites.…”

Section: Methodsmentioning

confidence: 99%

Enzyme-Free Colorimetric Immunoassay for Protein Biomarker Enabled by Loading and Disassembly Behaviors of Polydopamine Nanoparticles

Xing

Tang

et al. 2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

In this work, a mussel-inspired polydopamine (PDA) nanoparticle with biocompatible and reactive surface characteristics was desirably incorporated with high loading capacity and pH-induced disassembly-releasing behavior toward Fe(III) ions to develop an enzyme-free colorimetric immunoassay. The catechol functional network of PDA can act as a scaffold to coordinate with large amounts of Fe(III) ions to form the PDA-Fe(III) NPs whose coordination state can be tailored by changing the pH values. In detail, PDA-Fe(III) NPs can be maintained in a disassembled tri-coordinate state under alkaline conditions while the highly loaded Fe(III) ions can be easily released under acid conditions to react with ferrocyanide for the in situ generation of Prussian blue (PB) NPs. The detection sensitivity of prostate-specific antigen (PSA) was significantly improved, owing to the high peroxidase-like activity of PB NPs that triggered excellent catalytic effect by the colorimetric reaction. In addition, favorable linearity was found in the range of 0.0005–20 ng mL–1 with a low detection limit of 0.84 pg mL–1 (S/N = 3). Furthermore, excellent selectivity and reproducibility were exhibited by the developed enzyme-free colorimetric immunoassay. It is believed that this proposed PDA-Fe(III) NP-based enzyme-free colorimetric system will offer a facile and reliable tool for the sensitive detection of PSA and other cancer biomarkers in human serum.

show abstract

Section: Methodsmentioning

confidence: 99%

Enzyme-Free Colorimetric Immunoassay for Protein Biomarker Enabled by Loading and Disassembly Behaviors of Polydopamine Nanoparticles

Xing

Tang

et al. 2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…There are clinically approved immunoassays for PSA detection [190,191] and numerous electrochemical aptasensors aiming at inexpensive and robust ways of PSA electroanalysis have been reported and intensively overviewed [192][193][194][195][196][197][198][199]. Here, we update only few very recent reports.…”

Section: Prostate-specific Antigenmentioning

confidence: 98%

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

Malecka

Mikuła

Ferapontova

2021

Sensors

View full text Add to dashboard Cite

Improved outcomes for many types of cancer achieved during recent years is due, among other factors, to the earlier detection of tumours and the greater availability of screening tests. With this, non-invasive, fast and accurate diagnostic devices for cancer diagnosis strongly improve the quality of healthcare by delivering screening results in the most cost-effective and safe way. Biosensors for cancer diagnostics exploiting aptamers offer several important advantages over traditional antibodies-based assays, such as the in-vitro aptamer production, their inexpensive and easy chemical synthesis and modification, and excellent thermal stability. On the other hand, electrochemical biosensing approaches allow sensitive, accurate and inexpensive way of sensing, due to the rapid detection with lower costs, smaller equipment size and lower power requirements. This review presents an up-to-date assessment of the recent design strategies and analytical performance of the electrochemical aptamer-based biosensors for cancer diagnosis and their future perspectives in cancer diagnostics.

show abstract

“…As we all know, biomarker detection is of great reference significance to the screening, risk stratification, and relapse monitoring of PCa [60]. As incredible progresses have been made in nanotechnology, biosensors based on the principles of fluorescence [61], colorimetry [62], electrochemical [63], and signal amplification [64] have been widely applied in the biomedical field due to their advantages of good selectivity, high sensitivity, rapid analysis, and low cost [65].…”

Section: Detection Of Prostate Cancer Biomarkersmentioning

confidence: 99%

The Aptamer Functionalized Nanocomposite Used for Prostate Cancer Diagnosis and Therapy

Feng

Zhu

Wang

et al. 2022

Journal of Nanomaterials

View full text Add to dashboard Cite

Prostate cancer is one of the major malignancies that threaten men’s health all over the world. Due to the lack of specific symptoms and signs in the early stage, as well as the limitations of existing detection methods, it is difficult to achieve early diagnosis for prostate cancer. As short single-stranded oligonucleotides (DNA or RNA) with specific 3D structure which can be produced using an in vitro selection process termed systematic evolution of ligands by exponential enrichment (SELEX), aptamers can specifically bind to the corresponding targets. They have become a class of novel targeting ligand for accurate diagnosis and effective treatment of cancer. Owing to distinctive physicochemical features, and some other special properties such as easy modifiability, good biocompatibility, being easily coupled with other ligands, nanomaterials are extensively used in biological medical field research. Enlighteningly, the combination of aptamers with nanomaterials, including metal nanoparticles, nanosilica, quantum dots, and carbon nanomaterials, can enhance the ability of nanomaterials to recognize tumor cells, which is beneficial to overcome the shortcomings such as low sensitivity in early detection and lack of specificity of traditional antineoplastic drugs, thus, clinically helpful to improve the early metaphase diagnosis rate, providing a technical guarantee for the “personalized treatment” strategy for prostate cancer. Herein, we mainly review the basic and applied research of aptamer functionalized nanocomposite in prostate cancer diagnosis and treatment, including biosensing, bioimaging, and cancer therapy, hoping to provide new ideas for prostate cancer diagnosis and treatment.

show abstract

Advances in prostate specific antigen biosensors-impact of nanotechnology

Cited by 42 publications

References 163 publications

Enzyme-Free Colorimetric Immunoassay for Protein Biomarker Enabled by Loading and Disassembly Behaviors of Polydopamine Nanoparticles

Enzyme-Free Colorimetric Immunoassay for Protein Biomarker Enabled by Loading and Disassembly Behaviors of Polydopamine Nanoparticles

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

The Aptamer Functionalized Nanocomposite Used for Prostate Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About